Too close for comfort: FDA shouldn’t loosen conflict rules for its expert panels
Never mind the conflicts, there are drugs to approve.
In a sorry turn of events, the Food and Drug Administration is facing a confidence-draining debacle thanks to its controversial approval of a pricey Alzheimer’s drug for which evidence appears suspect, at best.
